FY2026 EPS Forecast for OPKO Health Increased by Analyst

OPKO Health, Inc. (NASDAQ:OPK) – Equities research analysts at HC Wainwright upped their FY2026 earnings estimates for shares of OPKO Health in a research note issued to investors on Tuesday, July 28th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will earn ($0.23) per share for the year, up from their previous forecast of ($0.30). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for OPKO Health’s Q1 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.29) EPS.

Other equities analysts have also issued reports about the company. Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Barrington Research lowered OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $1.55.

OPKO Health Stock Down 17.3%

Shares of NASDAQ:OPK opened at $1.36 on Thursday. The firm has a fifty day moving average of $1.38 and a 200 day moving average of $1.27. OPKO Health has a 52-week low of $0.98 and a 52-week high of $1.73. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.17 and a current ratio of 3.35. The firm has a market capitalization of $1.03 billion, a PE ratio of -15.17 and a beta of 1.48.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.07. The firm had revenue of $163.58 million for the quarter, compared to analysts’ expectations of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The company’s revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.19) EPS.

Institutional Trading of OPKO Health

Several large investors have recently modified their holdings of OPK. Zacks Investment Management purchased a new position in shares of OPKO Health during the fourth quarter valued at approximately $27,000. StoneX Group Inc. purchased a new position in shares of OPKO Health during the 4th quarter worth approximately $27,000. Apella Capital LLC bought a new position in shares of OPKO Health in the 1st quarter worth approximately $34,000. Cibc World Markets Corp purchased a new position in shares of OPKO Health in the 4th quarter valued at approximately $34,000. Finally, EP Wealth Advisors LLC bought a new stake in shares of OPKO Health during the 4th quarter valued at $37,000. 64.63% of the stock is owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.